相关实验视频

Updated: Jun 24, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

一种针对cAMP偏差信号优化的GLP-1模拟物改善了肥胖小鼠的体重减轻

Jonathan D Douros¹, Aaron Novikoff², Barent DuBois¹

¹Novo Nordisk Research Centre Indianapolis, Indianapolis, IN, USA.

Molecular metabolism

|March 29, 2025

概括

在临床前模型中,偏差型葡萄糖类1 (GLP-1) 受体 (GLP-1R) 激动剂,而不仅仅是那些具有高cAMP强度的激动剂,在临床前模型中显示出更大的体重减轻. 信号偏差预测肥胖药物疗法的体内疗效.

科学领域:

药理学药理学是指药理学的学科.
内分泌学在内分泌学.
药物发现药物发现药物发现

背景情况:

葡萄糖类1受体 (GLP-1R) 激动性是肥胖药物治疗的关键,目前的药物针对G蛋白α (Gsα) 信号和cAMP产生进行了优化.
新出现的证据表明,局部,偏向的GLP-1R激动剂可能比完全激动剂提供更好的减肥效果.
这种偏差涉及减少Gsα信号和不成比例的β-arrestin招募相对于本地配体.

研究的目的:

调查是否在体外信号偏差,包括cAMP和β-arrestin通路,更好地预测饮食诱导的肥胖 (DIO) 动物的减肥有效性,而不是单独的cAMP功效.
评估一种具有偏差信号配置的新型延长GLP-1模拟物 (NNC5840).

主要方法:

评估了体外GLP-1R信号偏差与DIO动物体重减轻之间的相关性.
描述了一种新型GLP-1模拟物NNC5840.0的体外信号特征 (cAMP和β-arrestin).
在DIO小鼠中,比较了NNC5840在体内减肥效果与塞马格卢提德的效果.

主要成果:

在DIO小鼠中,信号偏差与GLP-1R激动剂介导的体重减轻显著相关.
在实验室中,NNC5840显示了部分Gsα,cAMP偏差的GLP-1R信号配置.
与DIO小鼠中的semaglutide相比,NNC5840实现了优越的最大体重减轻,体内功效降低,但最大疗效增加.

结论:

偏差激发性是GLP-1R激发剂体内疗效的强有力的预测因素,独立于cAMP强度或药理动力学.
评估目标受体信号的整体查策略可能会产生更有效的肥胖药物候选者.
需要进一步研究,以了解结构修改如何影响偏向GLP-1R激动剂的生理化学性质.

关键词:

有偏见的激进主义.这就是GLP-1.肥胖问题肥胖问题塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents

Published on: November 1, 2019

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

相关概念视频

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Global Regulatory Systems

Global Regulatory Systems

Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...